Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
ID: 356552Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $400K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356552

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-022.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)," aimed at establishing Recruitment Sites (RS) for enrolling individuals with Type 1 diabetes (T1D) who are at risk of nephropathy. This initiative seeks applications for a longitudinal cohort study that will involve obtaining kidney biopsies and conducting comprehensive clinical phenotyping, with a focus on ethical practices and inclusivity to enhance understanding of T1D nephropathy and identify potential therapeutic targets. The funding opportunity has a budget of approximately $1.3 million, with individual awards of up to $400,000 in direct costs annually, and key deadlines include a letter of intent due on November 11, 2024, with applications closing on December 10, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DK-25-022-Full-Announcement.html
    RFA-DK-25-022.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity aimed at establishing Recruitment Sites (RS) focused on enrolling individuals with Type 1 diabetes (T1D) at risk of nephropathy. The initiative seeks applications for a longitudinal cohort study to obtain kidney biopsies and conduct comprehensive clinical phenotyping linked to social determinants of health. Emphasizing ethical practices, participant safety, and inclusivity, the program aims to enhance understanding of T1D nephropathy by identifying molecular pathways and potential therapeutic targets while leveraging the Kidney Precision Medicine Project (KPMP). No clinical trials are permitted under this funding opportunity, with a budget of approximately $1.3 million for 2 to 3 awards, each expected to include up to $400,000 in direct costs annually. Applicants should demonstrate multidisciplinary expertise and capabilities to recruit diverse cohorts, ensuring compliance with established KPMP protocols and governance. The application deadlines begin with a letter of intent due on November 11, 2024. This opportunity reflects the commitment to improve outcomes for individuals with T1D and tackle the significant burden associated with diabetic kidney disease.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for a cooperative agreement aimed at advancing research on Type 1 Diabetic nephropathy (T1D). This initiative seeks applications from Recruitment Sites (RS) to enroll adult and pediatric patients with T1D, particularly those at high risk for diabetic nephropathy, into a longitudinal cohort study, which will include protocol-based kidney biopsies. The research will leverage existing resources from the Kidney Precision Medicine Project (KPMP) to create a Kidney Tissue Atlas, identify disease subgroups, and explore novel therapeutic targets. The estimated total program funding for this opportunity is $1.3 million, with the NOFO expected to be published in fall 2024 and applications due in late fall 2024. Interested applicants are encouraged to reach out to the NIDDK contacts provided in the announcement for further information.
    Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition Funding Opportunity titled "Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers" (T1DAPC-CCs), aimed at establishing a clinical consortium to study diabetes incidence following acute pancreatitis episodes, with a focus on type 1 diabetes. This initiative seeks applications from previously funded Clinical Centers to continue a longitudinal observational study that investigates the incidence, etiology, and risk factors associated with diabetes emerging after acute pancreatitis, emphasizing collaboration among consortium members and effective data collection strategies. The funding amount is capped at $350,000 annually, with a project timeline extending up to five years, and applications are due by November 19, 2024, with the earliest anticipated award start in July 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Single Source for the Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for a cooperative agreement to establish the Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC). The primary objective is to conduct a longitudinal observational study, known as the DREAM study, which will investigate the incidence and mechanisms of diabetes that develop following episodes of acute pancreatitis. This initiative is crucial for understanding the relationship between acute pancreatitis and the onset of diabetes, particularly type 1 diabetes, and aims to identify genetic and environmental risk factors in a diverse population. Interested applicants must submit their proposals by November 19, 2024, with a funding ceiling of $800,000, and can direct inquiries to grantsinfo@nih.gov for further information.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for a cooperative agreement to support the continuation of the Human Pancreas Analysis Program for Type 1 Diabetes (HPAP-T1D) at the University of Pennsylvania. This initiative aims to enhance research on Type 1 Diabetes by systematically collecting and analyzing human pancreatic tissues and immune cells from patients, thereby advancing the understanding of disease mechanisms and identifying potential biomarkers for early intervention. The program is critical for fostering collaborative translational research within the Human Islet Research Network, which seeks innovative strategies to protect and replace functional human beta cell mass. The total funding available is $7.5 million over four years, with applications due by October 24, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small Research Project Grants (R01s) aimed at clinical trials focused on diseases under the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative encourages the submission of pilot and feasibility clinical trials that will provide foundational data for larger, definitive trials intended to improve the prevention and treatment of various health conditions, without the requirement of preliminary efficacy data. The program supports innovative research ideas and emphasizes equitable recruitment from diverse populations, with a maximum grant duration of three years and funding up to $200,000 per year. Interested applicants can find more information and submit their applications by May 7, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Polycystic Kidney Disease Core Centers (U54 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Polycystic Kidney Disease (PKD) Core Centers through a Notice of Funding Opportunity (NOFO) aimed at enhancing national research efforts in PKD. The initiative seeks to establish four Core Centers that will collaborate within the PKD Research Resource Consortium, focusing on developing and sharing essential research tools and resources while promoting scientific diversity and engagement among a wide range of investigators. Approximately $3.44 million in funding is anticipated for FY 2025, with applications due by November 15, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Kidney Technology Development Research Education Program (R25), aimed at fostering educational initiatives that encourage diverse individuals to pursue careers in nephrology and kidney technology development. This program seeks applications from institutions proposing innovative educational activities, including hands-on research projects, multidisciplinary teamwork, and training in entrepreneurship and regulatory processes, with a focus on recruiting undergraduate, graduate, and medical students from engineering and quantitative backgrounds. With a total funding allocation of $300,000 for FY 2025 and FY 2026, applications are due by June 15, 2025, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-009.html.